Page 11 - Noble-Virtual-Healthcare-2024

Atossa Therapeutics, Inc.

SELECTED FINANCIAL ITEMS ATOS

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.10) (7.79) (7.47) (9.02) (31.38)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (6.28) (9.83) (6.23) (7.75) (30.09)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 116.20 108.36 101.70 96.25 96.25
Cash & Short Term Investments 103.87 99.39 94.03 88.46 88.46
% of Assets 89% 92% 92% 92% 92%
Current Assets -Total 110.87 106.00 97.65 92.22 92.22
% of Assets 95% 98% 96% 96% 96%
Total Liabilities 2.94 3.48 3.44 5.24 5.24
% of Assets 3% 3% 3% 5% 5%
Current Liabilities - Total 2.94 3.48 3.44 5.24 5.24
% of Assets 3% 3% 3% 5% 5%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 113.26 104.88 98.25 91.02 91.02
% of Assets 97% 97% 97% 95% 95%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.02) (4.47) (3.88) (5.57) (20.94)
Net Cash Flow - Investing NA (0.01) (0.00) 0.00 (0.01)
Net Cash Flow - Financing NA NA (1.48) 0.00 (1.48)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference